SER News & Events

Serina Therapeutics announced Greg Bailey, a current board director, will assume the role of co-chairman of the board of directors. Greg Bailey will serve as co-chairman of the board of directors of Serina Therapeutics, alongside Simba Gill.

Serina Therapeutics announced that it has dosed the first patient in its Phase 1b registrational clinical trial evaluating SER-252 in patients with advanced Parkinson's disease.

Serina Therapeutics announced that the first patient has been enrolled in the company's Phase 1b registrational trial evaluating SER-252 in patients with advanced Parkinson's disease. The Phase 1b registrational study is designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of SER-252 in patients with advanced Parkinson's disease whose symptoms are inadequately controlled by current standard-of-care therapies. Serina remains on track to initiate dosing during the current quarter, consistent with previously disclosed guidance.